Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma

Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma

Justin J Kuhlman,1 Muhamad Alhaj Moustafa,2 Liuyan Jiang,3 Jing Wang,1 Vivek Gupta,4 Han W Tun2 1Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA; 2Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Pathology and Laboratory Medicine, Mayo Clini...

Full description

Bibliographic Details
Main Authors: Kuhlman JJ, Alhaj Moustafa M, Jiang L, Wang J, Gupta V, Tun HW
Format: Article
Language:English
Published: Dove Medical Press 2022-04-01
Series:Blood and Lymphatic Cancer: Targets and Therapy
Subjects:
newly diagnosed primary central nervous system lymphoma
ibrutinib
elderly adults
relapsed/refractory primary central nervous system lymphoma
clinical outcomes
Online Access:https://www.dovepress.com/long-term-survival-with-ibrutinib-therapy-in-elderly-patients-with-new-peer-reviewed-fulltext-article-BLCTT

Internet

https://www.dovepress.com/long-term-survival-with-ibrutinib-therapy-in-elderly-patients-with-new-peer-reviewed-fulltext-article-BLCTT

Similar Items